SCHEMBL698056

SCHEMBL698056

COc1cc(CO)ccc1OCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.63
RAB9A P51151 5/20 0.63
POLB P06746 1/20 0.63
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
BCHE P06276 1/20 0.60
HPGD P15428 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
KDM4E B2RXH2 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C9 P11712 1/20 0.59
BLM P54132 1/20 0.59
MTNR1A P48039 2/20 0.59
MTNR1B P49286 2/20 0.59
APP P05067 1/20 0.59
PKM P14618 1/20 0.57
ABCB1 P08183 1/20 0.57
ABCG2 Q9UNQ0 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31725848 1.00 NPC1 (0.63) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL31361425 0.94 BCHE (0.60) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL3239903 0.94 BCHE (0.60) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL584781 0.90 SLC2A1 (0.56) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL30280404 0.90 SLC2A1 (0.56) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL31040308 0.89 NPC1 (0.52) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL30027542 0.89 NPC1 (0.52) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL1322956 0.88 KDM4E (0.64) NPC1RAB9AMEN1KMT2ABCHE
SCHEMBL21377514 0.87 NPC1 (0.63) NPC1RAB9APOLBKDM4EAPP
SCHEMBL6035606 0.86 MEN1 (0.60) NPC1RAB9APOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119707647-A Preparation method of dendrobe phenol 安徽中医药大学 2025-03-28 CN claimed
CN-114773989-A Anti-silver colloid diffusion agent, preparation method and application thereof 苏州瑞港环保科技有限公司 2022-07-22 CN claimed
US-20140142279-A1 Method for peptide synthesis LALEZARI IRAJ (US) 2014-05-22 US claimed
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 US claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US claimed
CN-119707647-A Preparation method of dendrobe phenol 安徽中医药大学 2025-03-28 CN disclosed
CN-119707647-A Preparation method of dendrobe phenol 安徽中医药大学 2025-03-28 CN disclosed
CN-118112898-A Photoresist stripping liquid and application thereof 芝普企业股份有限公司 2024-05-31 CN disclosed
CN-112190571-B Application of gastrodia tuber source derivative in preparing medicine for treating inflammatory bowel disease 中国医学科学院药物研究所 2023-05-05 CN disclosed
CN-112190570-B Application of gastrodia tuber source derivative in preparing medicine for treating acute or chronic pain 中国医学科学院药物研究所 2023-05-05 CN disclosed
US-11505617-B2 Benzodiazepine derivatives IMMUNOGEN, INC. (US) 2022-11-22 US disclosed
CN-114773989-A Anti-silver colloid diffusion agent, preparation method and application thereof 苏州瑞港环保科技有限公司 2022-07-22 CN disclosed
WO-2001047892-A1 TRICYCLIC PROTEIN KINASE INHIBITORS WYETH (US) 2001-07-05 WO disclosed
EP-1112262-A1 SUBSTITUTED $g(g)-PHENYL-$g(D)-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO Inflazyme Pharmaceuticals, Ltd. (CA) 2001-07-04 EP disclosed
US-6210816-B1 Translucent xerographic recording substrates XEROX CORPORATION 2001-04-03 US disclosed
WO-2000014083-A1 SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO INFLAZYME PHARMACEUTICALS LTD. (CA) 2000-03-16 WO disclosed
WO-1998040472-A2 CARBOXYLIC ACID REDUCTASE, AND METHODS OF USING SAME UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 1998-09-17 WO disclosed
US-5795759-A Carboxylic acid reductase, and methods of using same THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 1998-08-18 US disclosed
US-5622137-A FOR USE IN TESTING COOKED FOODS TRANS WORLD SERVICES (US) 1997-04-22 US disclosed
EP-0613879-A1 PHELLODENDRINE ANALOGS AND ALLERGY TYPE IV SUPPRESSOR CONTAINING THE SAME AS ACTIVE INGREDIENT TSUMURA & CO. (JP) 1994-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140142279-A1 Method for peptide synthesis VIP, DNPEP, NGLY1 NPC1 972/4885RAB9A 2875/4885POLB 3368/4885
US-11505617-B2 Benzodiazepine derivatives GABBR1, GABRB1, GABRA1 NPC1 1245/4885RAB9A 3800/4885POLB 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.